Pfizer Inc. (PFE) To Go Ex-Dividend on November 6th

Pfizer Inc. (NYSE:PFE) declared a quarterly dividend on Tuesday, October 6th. Investors of record on Friday, November 6th will be paid a dividend of $0.43 per share by the biopharmaceutical company on Monday, December 7th. This represents a $1.72 dividend on an annualized basis and a yield of 6.2%. The ex-dividend date of this dividend is Friday, November 6th.

Pfizer has decreased its dividend by an average of 0.1%per year over the last three years and has raised its dividend annually for the last 16 consecutive years. Pfizer has a payout ratio of 55.8% indicating that its dividend is sufficiently covered by earnings. Analysts expect Pfizer to earn $2.95 per share next year, which means the company should continue to be able to cover its $1.72 annual dividend with an expected future payout ratio of 58.3%.

Pfizer Trading Up 1.7%

PFE opened at $27.96 on Thursday. The firm has a market capitalization of $159.39 billion, a price-to-earnings ratio of 36.80, a PEG ratio of 1.85 and a beta of 0.32. Pfizer has a one year low of $23.62 and a one year high of $29.21. The business has a 50 day simple moving average of $27.56 and a two-hundred day simple moving average of $26.48. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. The company had revenue of $15.03 billion during the quarter, compared to analyst estimates of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The firm’s revenue was up 2.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts predict that Pfizer will post 2.98 EPS for the current year.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA approved Pfizer’s TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab as a front-line maintenance treatment for adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction therapy. The expanded indication gives Pfizer earlier access to patients in the metastatic-treatment pathway and could broaden TUKYSA’s commercial opportunity. Pfizer’s TUKYSA Gets FDA Nod for Front-Line HER2+ Breast Cancer Maintenance
• Positive Sentiment: Pfizer reported positive Phase 3 results for oral LITFULO in nonsegmental vitiligo, showing meaningful facial and total-body repigmentation with a favorable tolerability profile. Planned regulatory submissions could expand the drug’s use and strengthen Pfizer’s immunology portfolio. Pfizer Posted Positive Phase 3 Vitiligo Results for LITFULO
• Positive Sentiment: The board declared a quarterly dividend of $0.43 per share, or $1.72 annualized, payable December 7 to shareholders of record November 6. The sizable yield may help support demand for PFE among income-oriented investors. Pfizer Declares $0.43 Fourth-Quarter Dividend
• Neutral Sentiment: Pfizer plans to cut approximately 330 jobs at its Sicily, Italy, plant. The move may reduce costs as part of broader restructuring, but it also highlights pressure to streamline operations. Pfizer to Cut Around 330 Jobs in Italy
• Negative Sentiment: Investor commentary remains cautious because Pfizer faces a challenging growth period, recently reported a quarterly loss, and has paid dividends well above reported earnings in some periods. Analysts are also watching competition to the Prevnar vaccine franchise, which generated substantial revenue for Pfizer. Pfizer Stock: Buy, Sell, or Hold?

About Pfizer

Pfizer Inc (NYSE:PFE) is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research and commercial activities focus on areas including oncology, inflammation and immunology, internal medicine, hospital care and vaccines.

The company’s portfolio includes widely used products such as the Prevnar family of pneumococcal vaccines, Ibrance for certain breast cancers, Eliquis for preventing blood clots, Xeljanz for inflammatory conditions, and Vyndaqel for transthyretin amyloidosis.